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Guidance on the indications for starting antiretroviral 
therapy (ART) and the preferred initial drugs has evolved 
substantially over the past 15 years. These changes were 
the result of a better understanding of the rate of disease 
progression and the high early morbidity and mortality. 
There is now a better appreciation of the long-term implications of early 
therapy and how to sequence the available drugs. 
Which children need ART?
The 2013 World Health Organization (WHO) and South African 
(SA) ART guidelines[1,2] recommend starting ART for all children 
<5 years of age and fast-tracking those who are very young and have 
severe disease (Table 1).
In the absence of ART, the majority of infants progress to AIDS and 
death within 18 months.[3] The strategy for ART initiation in all infants 
was studied in the Children with HIV Early Antiretroviral (CHER) 
trial.[4] Early ART was compared with a deferred approach in infants 
<12 weeks of age and with a baseline CD4+ ≥25%. Infants entered 
the trial at a median of 7 weeks of age. Children on early therapy had 
a significant reduction in mortality and HIV progression.[4] Some 
notable advantages were a reduction in tuberculosis (TB) incidence[4] 
and an improvement in developmental outcomes.[5] Griffiths Mental 
Development Scales scores were significantly higher for children who 
started early treatment (106.3 v. 100.1; p=0.02). Early treatment was 
also associated with higher locomotor scores (97.7 v. 88.9; p<0.001).[5]
In a subsequent retrospective study of infants who started therapy 
by 8 weeks of age under programmatic conditions, 62% already had 
advanced disease, indicating that more should be done to diagnose 
and treat infants even earlier.[6] Very early therapy in the neonatal 
period is possible despite challenges in drug options and dosing. The 
only drugs that have been studied extensively in term and preterm 
infants are zidovudine (ZDV) and lamivudine (3TC). One study of 
HIV-infected Canadian infants that initiated therapy within 72 hours[7] 
and the case of the Mississippi baby suggest that very early therapy may 
limit the HIV reservoir.[8]   
The evidence for starting children between 2 and 5 years of age 
is less clear.[9] The current recommendations are only partially 
based on evidence of clinical benefit, but are also an attempt to 
simplify complex operational and programmatic issues. The Pediatric 
Randomized Early v. Deferred Initiation in Cambodia and Thailand 
(PREDICT) trial enrolled children of 1 - 12 years of age without 
AIDS-defining illnesses and relatively high CD4+ counts. Outcomes 
with deferring ART were equivalent to immediate ART.[10] There 
was no significant difference with regard to viral suppression, CD4+ 
percentage after ART initiation or toxicity. Of note, intelligence 
quotient did not differ 3 years after study entry, regardless of ART 
strategy.[11] However, it is likely that the neurological benefit of 
early ART was already forfeited in this group. It is important to 
note that the definition of HIV-associated encephalopathy used in 
both the CHER[4] and PREDICT[11] trials did not include less severe 
manifestations of neurodevelopmental dysfunction. 
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Since 2004, when antiretroviral therapy (ART) was first available to children through the National Department of Health, there has 
been significant progress in preventing and treating paediatric HIV. Large cohort studies and prospective trials confirmed that young 
children require early diagnosis with rapid access to ART regardless of CD4+ lymphocyte count. Studies also confirmed the importance of 
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require new skills to assist children with transition into adulthood. In this article we focus on the care of infants and children.
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Table 1. Indications for starting antiretroviral therapy and 
fast-tracking
Age Indication Fast-tracking
Birth - 5 years All children Infants <1 year of age
Hospitalised children
MDR- or XDR-TB
WHO stage 3/4 disease
Severe immune suppression
5 - 15 years WHO stage 3/4 
disease, or CD4+ 
<350 cells/µL*
WHO stage 3/4 disease
MDR- or XDR-TB
CD4+ <200 cells/μL or 
CD4+ <15%
WHO = World Health Organization; MDR-TB = multidrug-resistant tuberculosis; 
XDR-TB = extensively drug-resistant TB.
*From January 2015 new guidelines for adults will provide therapy at CD4+ <500 cells/µL. 
Paediatric guidelines will follow suit.
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Rationale for the current national first 
regimen
Initially, the ART programme used stavudine (d4T) as a first-line 
nucleoside reverse transcriptase inhibitor (NRTI). d4T is easy to 
use, has very few initial complications and is inexpensive. Serious 
late complications such as lipoatrophy and lactic acidosis led to 
replacement by abacavir (ABC) for children and tenofovir (TDF) 
for adults.[2] ABC has an excellent short- and long-term side-
effect profile and requires only clinical monitoring soon after 
initiation.[12] The Paediatric European Network for Treatment of 
AIDS (PENTA) 5 study clearly showed that ABC plus 3TC combined 
with unboosted nelfinavir (NFV) performed better than ZDV plus 
3TC or ZDV plus ABC with unboosted-NFV.[12] ABC as first line 
may also select for more ‘manageable’ resistance patterns in failing 
children. However, since switching to ABC plus 3TC as the first-line 
NRTI backbone in children, there are concerns about its efficacy in SA 
children.[13] This was highlighted in a retrospective study with a number of 
confounders, including the relative lack of rigor of data collection 
under programmatic conditions and rifampicin co-treatment for 
children with TB on lopinavir/ritonavir (LPV/r)-based regimens.[14] 
More recently, the randomised Pharmacokinetics and Adherence/
Acceptability of Simple Antiretroviral Regimens (CHAPAS-3) study 
showed that ABC performed as well as both d4T and ZDV when 
combined with 3TC as NRTI backbone with a non-NRTI (NNRTI).[15]
ABC hypersensitivity reaction (HSR) is associated with 
HLA*B5701, HLA-DR7 and HLA-DQ3 genotypes.[16] HLA*B5701 is 
the most common risk factor. During the Antiretroviral Research for 
Watoto (ARROW) study of more than 1  200 HIV-infected infants 
from Uganda and Zimbabwe, HSR occurred in 0.2% of children.[17] 
The diagnosis is clinical and therapy should not be interrupted if the 
case definition is not met. After interruption for HSR, ABC cannot 
be re-initiated.
Children still receiving first-line d4T should be switched to ABC 
to avoid lipoatrophy if the viral load is undetectable. Children on 
efavirenz  (EFV) with a viral load of >1 000 copies/mL and those on 
LPV/r with a viral load of >5 000 copies/mL, should be managed as 
for treatment failure. When the viral load is detectable, but below 
these thresholds for regimen switching, a single drug substitution 
with ABC should not be done. If considered essential, consult an 
experienced clinician (Table 2).
TDF is licensed in the USA from the age of 2 years and is a first-line 
treatment recommendation by the WHO.[1] However, as TDF is only 
licensed from 18 years in SA and there are no available appropriate 
formulations, we currently do not support its routine use. Selected 
children with specific indications such as hepatitis B should be 
offered TDF, but bone and renal toxicity must be carefully monitored. 
The serum creatinine must be measured and the glomerular filtration 
rate calculated using an age-appropriate formula. When possible, 
bone density monitoring should be offered.
As the third drug in first-line ART, the protease inhibitor (PI) 
LPV/r is superior to nevirapine (NVP) in children <3 years of 
age, regardless of past NVP exposure.[18] In children started on 
ART >3 years of age, the PENPACT-1 study showed that, after 
4 years on ART, viral suppression and CD4+ count were similar 
on NNRTI and PI-based ART.[19] Of note, the PI most commonly 
used was unboosted nelfinavir, an unacceptable choice given 
current knowledge. LPV/r solution is not palatable and refusal 
of the drug is common in children. Also, there is concern about 
longer-term metabolic complications and cost. Co-treatment of 
TB requires additional ritonavir (RTV) boosting, taken separately 
from LPV/r. Switching suppressed children from LPV/r to NVP 
for those <3 years or EFV for those >3 years resulted in 
sustained viral suppression in the Nevirapine Resistance Study 
(NEVEREST) studies.[20,21] Although switching to EFV in children 
>3 years and to NVP in those <3 years was successful in some 
instances, currently infants failing prevention of mother-to-child 
transmission (PMTCT) have prolonged NNRTI exposure for at 
least 6 weeks, rather than only a single dose as in NEVEREST, thus 
increasing the risk of subsequent significant NNRTI resistance. 
In NEVEREST-2, failure occurred more often in children with 
baseline NNRTI resistance (plasma RNA >1 000 copies/mL) when 
switched to NVP than in those remaining on LPV/r (22% v. 10%; 
p=0.009).[19] Although routine switching from LPV/r to NNRTI 
is not part of the current guidelines, it can be considered on an 
individual basis in suppressed older children with intolerance 
or toxicity or in those who would benefit from EFV during TB 
treatment, but careful viral load monitoring soon after the switch 
is essential.
EFV for first-line therapy in children >3 years of age and weighing 
10 kg is still recommended, despite concern about prior exposure to 
NVP through PMTCT. Careful virological monitoring in children 
infected despite PMTCT is essential. The US Food and Drug 
Administration (FDA) recently approved EFV in children <3 years 
and weighing <10  kg. However, this is not thought to be a safe 
approach given our current PMTCT strategy.
Once-daily dosing
To simplify ART, once-daily dosing of ABC and 3TC was studied. 
Both can be given once daily from 20 kg and 3 years of age, although 
some experts recommend daily 3TC only from 25  kg.[22-24] The 
latest weight-based therapy chart allows for this (available on the 
SA HIV Clinicians Society website: http://www.sahivsoc.org). The 
availability of the lower-dose ABC tablets (60  mg) and ABC/3TC 
(600/300 mg) fixed-dose combination allows for simplification and 
reduction of pill burden and an earlier switch from liquid to solid 
formulations.  
Table 2. Recommended first regimen
Age Regimen
When to consider 
switching in failing 
children
All infants and 
children 
<3 years (or <10 kg)
ABC + 3TC + LPV/r Established on ART 
>4 - 6 months 
and viral load >5 000 
copies/mL on two 
occasions 2 - 3 months 
apart
Children
≥3 years (or ≥10 kg)
ABC + 3TC + EFV Established on ART 
>4 - 6 months
and viral load 
>1 000 copies/mL on 
two occasions  2 - 3 
months apart
Currently on d4T-
based regimen
Change d4T to ABC if
viral load is 
undetectable
If viral load >1 000 
copies/mL, manage as 
treatment failure
If viral load 50 - 1 000 
copies/mL – consult 
an expert 
d4T = stavudine; ABC = abacavir; 3TC = lamivudine; LPV/r = lopinavir/ritonavir; 
EFV = efavirenz; ART = antiretroviral therapy.
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LPV/r can be used daily in adults. In the Kaletra Once Daily 
Randomized Trial (KONCERT), 173 virally suppressed children 
weighing >15 kg and on LPV/r were randomised to daily (n=86) or 
twice-daily (n=87) dosing. Those given daily dosing were more likely 
to have low-level viraemia at week 48 (12 v. 7 children; p=0.196). The 
probability of viral rebound in the daily v. twice-daily group was 0.141 
(90% confidence interval (CI) 0.09 - 0.217) v. 0.08 (90% CI 0.044 - 0.145). 
In the greater majority the viraemia was suppressed without a dose 
change and new resistance rarely developed in either group. Participants 
preferred daily dosing.[25] 
Mycobacterium tuberculosis 
co-infection
TB remains a common problem in HIV-infected children. The 
incidence of TB disease is estimated at 23/100 child-years in HIV-
infected children in SA.[26] Access to ART remains an essential 
intervention to prevent TB, and in children on therapy rates have 
declined substantially.
Co-treatment with rifampicin affects the metabolism of certain 
antiretroviral drugs, especially LPV/r, which may affect the virological 
outcomes. Limited data suggest that, unlike in adults, doubling the 
LPV/r dosage does not achieve adequate PI bioavailability in young 
children on rifampicin.[27] LPV/r ‘super-boosted’ with additional 
RTV, in order that the LPV and RTV have a 1:1 ratio, is the preferred 
strategy.
Outcomes in African children on ART
Despite access to ART, 7% of children given ART die in the first year 
in a programmatic setting.[28]  In older children (mean age at starting 
4.3 years), virological suppression rates of 96% by 12 months are 
reported from Soweto.[29] In the P1060 study, approximately 80% of 
children on LPV/r achieved a viral load of <400 copies/mL at week 
24.[18] In the International epidemiologic Databases to Evaluate 
AIDS (IeDEA) cohort, children starting ART at around 3.5 years 
of age had a 20% rate of virological failure after 3 years.[30] The 
ARROW study confirmed this finding, with 83% of children on 
two NRTIs and an NNRTI having a viral load of <400 copies/mL 
after a median of 3.7 years on therapy.[17] Virological outcomes 
are equivalent to those in European or American children.[31] The 
CHER study also assessed the possibility of treatment interruption. 
Here, gains were modest and there was no arm receiving early 
continuous ART for comparison. Therefore, we cannot recommend 
this strategy.[32] 
Failure of first-line regimens
Poor adherence is the main reason for failure, but intolerance and 
drug interactions and/or drug toxicity are important contributors. 
Caregiver problems including poor physical and/or mental health, 
substance abuse, change in caregiver, multiple caregivers and 
family or household non-disclosure of HIV status are important 
contributors to failure. These factors should be explored in depth 
in failing children. As in adults, indications for resistance testing 
are driven by the availability of funds (Table 3). Children not taking 
any medication or who adhere poorly are unlikely to benefit from 
resistance testing. Furthermore, one may only detect resistance to 
current, not previous, medications. All resistance testing should 
be viewed in the context of full drug exposure history, including 
PMTCT. Children failing an initial regimen containing an NNRTI 
usually have resistance, but still have a powerful second regimen 
available. There are no studies in low-resource settings where 
delayed switching is common. However, adult data suggest that 
even with delayed switching after failing an NNRTI-based first 
line, an RTV-boosted PI with 2 NRTIs has a good outcome. 
Children failing LPV/r rarely have LPV/r resistance initially, 
unless previously given RTV monotherapy or TB therapy.[33,34] 
In children failing LPV/r as a first regimen, a resistance test and 
possibly LPV/r trough levels should be considered. We need more 
data on hair levels of LPV/r as a measure of long-term adherence 
before this strategy can be recommended. Resistance tests may not 
show PI resistance if the child was already switched to an NNRTI-
based regimen or if ART was interrupted. These results should 
be interpreted cautiously and an experienced clinician should be 
consulted. Limited data suggest that African children on third-line 
ART regimens can do very well.
Table 3. Possible indications for resistance testing in children
Scenario Rationale for testing
Transmission prevention failure
Mothers failing first-line or second-line therapy 
during pregnancy
Resistance may include more than NNRTI resistance with possible NRTI and even PI 
resistance transmitted to the infant
Infants exposed to prolonged NVP during breastfeeding Document resistance against second-generation NNRTI
Infants failing dual or triple post-exposure prevention Document resistance in the infant in order to plan therapy
First-line failure
First-line failure with NNRTI Document second-generation NNRTI resistance 
Potentially prevents switching NRTI in selected patients
First-line failure – boosted PI It is preferable that all such children are tested, as there may not be primary 
mutations conferring PI resistance. Adherence should be documented
Ritonavir full-dose therapy and currently on a 
boosted PI
Possible PI resistance
TB therapy during PI regimen, especially if 
inappropriately boosted or not boosted
Possible PI resistance
Second-line failure
All children Planning a suppressive third line 
NVP = nevirapine; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; TB = tuberculosis.
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Drugs recently licensed for SA 
children
Raltegravir (RGV), an integrase inhibitor, is registered in SA and is 
available as granules, 25 mg and 100 mg chewable tablets and 400 mg 
film-coated tablets. These formulations are not interchangeable as they 
are not bioequivalent. RGV can be used in combination therapy from 
the age of 1 month and 3 kg. Dosing is according to weight band and 
formulation specific. Currently, most SA children receiving RGV are 
on a third-line regimen with RTV-boosted darunavir (DRV). RGV 
efficacy was first reported in treatment-experienced children and youth 
in the P1066 study.[17]  However, it is a potential first-line option where 
there is a drug reaction or intolerance, provided the patient’s virus is 
fully susceptible to the other two drugs in the regimen. Its dosing with 
rifampicin-based TB therapy in children is being studied. RGV has a low 
resistance barrier and if patients fail this drug it should be discontinued 
to prevent resistance to the second-generation integrase inhibitor 
dolutegravir (DTG). DTG has only recently been studied in children.
Atazanavir (ATZ), a newer PI, is a first-line drug for children >6 years 
old, adolescents and adults in the USA. Dosing is according to weight 
bands, beginning at 15 kg. RTV boosting is mandatory until the age of 
13 years, with the dose remaining the same across weight bands. ATZ 
can be given daily. Currently, very few children are using ATZ owing 
to limited formulations available, but in older children who cannot 
tolerate LPV/r this drug may be considered. If such patients develop 
TB, rifampicin must be replaced with rifabutin, which requires 
dose adjustment. We recommend that an experienced clinician be 
consulted in these cases. Many patients on ATZ experience indirect 
hyperbilirubinaemia, which causes social discomfort but does not 
necessitate a therapeutic change.[35] 
Boosted DRV is one of the most durable PIs, with fewer side-
effects than LPV/r. Few PI-experienced children have more than 
one mutation, making it a useful option for third-line regimens and 
second line after failing LPV/r. Recent data on DRV in a once-daily 
regimen in ART-naive adolescents, support consideration in first-line 
therapy.[36] DRV is approved for children >6 years of age with 300 mg, 
150 mg and 75 mg tablets registered in SA. There is some concern 
about DRV in children <3 years of age, as infant rats experienced 
seizures and a high death rate when exposed to the drug.[37]
Etravirine (ETV), an NNRTI, is registered in SA. However, children 
who failed extended NVP prophylaxis or become infected through 
breastfeeding while their mothers received EFV often have a virus 
harbouring the Y181C mutation precluding the NNRTI.[38] There are 
no data for rilpivirine in children. This NNRTI is unaffected by Y181C.
Conclusion
Children graduating from the PMTCT programmes are increasingly 
exposed to multiple medications, which pose therapeutic challenges. 
There is a need to move from early to very early diagnosis and ART 
initiation, with its own set of challenges. There is increasing access to 
newly licensed drugs for failing children with complex disease, but 
we still lack palatable fixed-dose combinations as first-line therapy.
References
1. World Health Organization (WHO). Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating 
and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: WHO Press, 2013.
2. South African Department of Health, South African National AIDS Council. The South African 
Antiretroviral Treatment Guidelines. Pretoria: SA Department of Health, 2013.
3. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born 
to HIV-infected mothers in Africa: A pooled analysis. Lancet 2004;364:1236-1243. [http://dx.doi.
org/10.1016/S0140-6736(04)17140-7]
4. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected 
infants. N Engl J Med 2008;359:2233-2244. [http://dx.doi.org/10.1056/NEJMoa0800971]
5. Laughton B, Cornell M, Grove D, et al. Early antiretroviral therapy improves neurodevelopmental 
outcomes in infants. AIDS 2012;26:1685-1690. [http://dx.doi.org/10.1097/QAD.0b013e328355d0ce]
6. Innes S, Lazarus E, Otwombe K, et al. Early severe HIV disease precedes early antiretroviral therapy in 
infants: Are we too late? J Int AIDS Soc 2014;11(17):18914. [http://dx.doi.org/10.7448/IAS.17.1.18914]
7. Bitnun A, Samson L, Chun TW, et al. Early initiation of combination antiretroviral therapy in HIV-
1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells 
carrying HIV in peripheral blood. Clin Infect Dis 2014;59(7):1012-1019.
8. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in 
an infant. N Engl J Med 2013;369:1828-1835. [http://dx.doi.org/10.1056/NEJMoa1302976]
9. Siegfried N, Davies MA, Penazzato M, Muhe LM, Egger M. Optimal time for initiating antiretroviral 
therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old. Cochrane Database 
Syst Rev 2013;10:CD010309. [http://dx.doi.org/10.1002/14651858.CD010309.pub2]
10. Puthanakit T, Saphorn V, Ananworanich J, et al. Early versus deferred antiretroviral therapy for 
children older than 1 year infected with HIV (PREDICT): A multicentre, randomised, open-label trial. 
Lancet Infect Dis 2012;12: 933-941. [http://dx.doi.org/10.1016/S1473-3099(12)70242-6]
11. Puthanakit T, Ananworanich J, Vonthanak S, et al. Cognitive function and neurodevelopmental 
outcomes in HIV-infected children older than 1 year of age randomized to early versus deferred 
antiretroviral therapy: The PREDICT neurodevelopmental study. Pediatr Infect Dis J 2013;32: 501-
508. [http://dx.doi.org/10.1097/INF.0b013e31827fb19d]
12. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-
analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-
1 who have not previously been treated: The PENTA 5 randomized trial. Lancet 2002;359:733-740. 
[http://dx.doi.org/10.1016/S0140-6736(02)07874-1]
13. Technau KG, Lazarus E, Kuhn L, et al. Poor early virologic performance and durability of abacavir-
based first-line regimens for HIV-infected children. Pediatr Infect Dis J 2013;32:851-855.
14. Zanoni BC, Phungula T, Zanoni HM, France H, Feeney ME. Impact of tuberculosis cotreatment on 
viral suppression rates among HIV-positive children initiating HAART. AIDS 2011;25:49-55. [http://
dx.doi.org/10.1097/QAD.0b013e32833f9e04]
15. Musiime V, Kekitiinwa A, Mulenga V, et al. CHAPAS 3: A randomized trial comparing stavudine vs 
zidovudine vs abacavir as NRTI backbone in NNRTI-based first line ART in 478 HIV-infected children 
in Uganda and Zambia. Reviews in Antiviral Therapy and Infectious Diseases 2014;6.
16. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, 
and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 
2002;359(9308):727-732. [http://dx.doi.org/10.1016/S0140-6736(02)07873-X]
17. Nahirya-Ntege P, Musiime V, Naidoo B, et al. on behalf of the ARROW trial team. Low incidence 
of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Pediatr 
Infect Dis J 2011;30(6):535-537.
18. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum 
nevirapine exposure. N Engl J Med 2010;363:1510-1520. [http://dx.doi.org/10.1056/NEJMoa1000931]
19. PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease 
inhibitor versus nonnucleoside reverse transcriptase inhibitor and switch at higher versus low 
viral load in HIV-infected children: An open-label, randomised phase 2/3 trial. Lancet Infect Dis 
2011;11:273-283. [http://dx.doi.org/10.1016/S1473-3099(10)70313-3]
20. Kuhn L, Coovadia A, Strehlau R, et al. Switching children previously exposed to nevirapine to 
nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: Long-
term follow-up of a randomised, open-label trial. Lancet Infect Dis 2012;12(7):521-530. [http://dx.doi.
org/10.1016/S1473-3099(12)70051-8]
21. Coovadia A. Virologic efficacy of efavirenz maintenance therapy in nevirapine prophylaxis-exposed 
children. 21st Conference on Retroviruses and Opportunistic Infections (CROI), 3 - 6 March 2014, 
Boston, USA. Oral abstract 73.
22. Paediatric European Network for Treatment of AIDS (PENTA). Pharmacokinetic study of once-daily 
versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3 - <36 months. 
Antivir Ther 2010;15(3):297-305. [http://dx.doi.org/10.3851/IMP1532]
23. Bergshoeff A, Burger D, Verweij C, et al. Plasma pharmacokinetics of once- versus twice-daily 
lamivudine and abacavir: Simplification of combination treatment in HIV-1-infected children 
(PENTA-13). Antivir Ther 2005;10(2):239-246.
24. Musiime V, Kendall L, Bakeera-Kitaka S, et al. Pharmacokinetics and acceptability of once- versus 
twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. 
Antivir Ther 2010;15(8):1115-1124. [http://dx.doi.org/10.3851/IMP1695]
25. Lyall H. Final results of Koncert: A randomised noninferiority trial of QD vs BD LPV/r dosing in 
children. 21st Conference on Retroviruses and Opportunistic Infections (CROI), 3 - 6 March 2014, 
Boston, USA. Oral abstract 74LB.
26. Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ. Clinical presentation and outcome 
of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC 
Pediatr 2008; 8:1-12. [http://dx.doi.org/10.1186/1471-2431-8-1]
27. McIlleron H, Ren Y, Nuttall J, et al. Lopinavir exposure is insufficient in children given double doses of 
lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther 2011;16:417-421. 
[http://dx.doi.org/10.3851/IMP1757]
28. Davies MA, May MA, Bolton Moore C, et al. Prognosis of children with HIV-1 infection starting 
antiretroviral therapy in Southern Africa. A collaborative analysis of treatment programs. Pediatr 
Infect Dis J 2014;33:608-616. [http://dx.doi.org/10.1097/INF.0000000000000214]
29. Meyers T, Yoteieng M, Kuhn L, et al. Antiretroviral therapy responses among children attending a 
large public clinic in Soweto, South Africa. Pediatr Infect Dis J 2011;30(11):974-979. [http://dx.doi.
org/10.1097/INF.0b013e31822539f6]
30. Davies MA, Moultrie H, Eley B, et al. and International Epidemiologic Databases to Evaluate AIDS 
Southern Africa (IeDEA-SA) Collaboration. Virologic failure and second-line antiretroviral therapy 
in children in South Africa – the IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr 
2011;56:270-278. [http://dx.doi.org/10.1097/QAI.0b013e3182060610]
31. Peacock-Villada E, Richardson BA, John-Stewart GC. Post-HAART outcomes in pediatric 
populations: Comparison of resource-limited and developed countries. Pediatrics 2011;127:e423-441. 
[http://dx.doi.org/10.1542/peds.2009-2701
32. Cotton MF, Violari A, Otwombe K, et al. Early time-limited antiretroviral therapy versus deferred therapy 
in South African infants infected with HIV: Results from the children with HIV early antiretroviral (CHER) 
randomised trial. Lancet 2013;382:1555-1563. [http://dx.doi.org/10.1016/S0140-6736(13)61409-9]
33. Van Zyl GU, van der Merwe L, Claassen M, et al. Protease inhibitor resistance in South African 
children with virologic failure. Pediatr Infect Dis J 2009;28:1125-1127.
34. Taylor BS, Hunt G, Abrams EJ, et al. Rapid development of antiretroviral drug resistance mutations in 
HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South 
Africa. AIDS Res Hum Retroviruses 2011;27:945-956.
35. O’Mara E, Randall D, Passarell J, Steinberg S, Grasela D. Population pharmacodynamic assessment of 
atazanavir exposure, uridine diphosphate-glucuronosyl transferase (UGT) 1A1 genotype and safety 
in healthy subjects. 42nd Interscience Congress on Antimicrobial Agents and Chemotherapy, 27 - 30 
September 2002, San Diego, Calif., USA. Abstract A-1253.
36. Flynn P, Komar S, Blanche S, et al. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-
naïve, HIV-1-infected adolescents. Pediatr Infect Dis J 2014;33:940-945. [http://dx.doi.org/10.1097/
INF.0000000000000308]
37. US Food and Drug Administration. Prezista Drug Label. Clinical Review of Darunavir, 2012. 
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/
UCM346671.pdf (accessed 30 October 2014).
38. Persaud D, Bedri A, Ziemniak C, et al. AIDS Res Hum Retroviruses 2011;27(8):823-829. [http://dx.doi.
org/10.1089/AID.2010.0346]
